Payment overview · 2025
General Payments
$2,000.87
23 reported records · 12 companies
Healthcare provider profile · identity verified
Naresh A Mori, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ROCK HILL, SC · NPI 1629281282
Verified facts
What the public records show
CMS Open Payments records show Naresh A Mori, MD received $2,000.87 in general payments during 2025 across 23 reported records.
Philips North America LLC accounted for 49.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Adempas by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Adempas by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $985.47 | 49.2% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $357.33 | 17.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $145.69 | 7.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.14 | 6.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $109.20 | 5.5% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $78.96 | 4.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $51.83 | 2.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.53 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.19 | 1.9% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $32.20 | 1.6% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $25.64 | 1.3% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.69 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,332.99 | 21 |
| Travel and Lodging | $667.88 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $582.50 | 2 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $402.97 | 3 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $357.33 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $145.69 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.14 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $109.20 | 1 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $78.96 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $51.83 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 35 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
98 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 424 | 169 |
| Eliquis | Apixaban | 423 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 400 | 184 |
| Carvedilol | Carvedilol | 337 | 152 |
| Spironolactone | Spironolactone | 299 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 129 |
| Clopidogrel | Clopidogrel Bisulfate | 274 | 137 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 94 |
| Furosemide | Furosemide | 182 | 111 |
| Losartan Potassium | Losartan Potassium | 153 | 82 |
| Jardiance | Empagliflozin | 124 | 46 |
| Valsartan | Valsartan | 113 | 46 |
| Entresto | Sacubitril/Valsartan | 98 | 37 |
| Xarelto | Rivaroxaban | 96 | 38 |
| Farxiga | Dapagliflozin Propanediol | 86 | 35 |
| Lisinopril | Lisinopril | 83 | 45 |
| Torsemide | Torsemide | 80 | 41 |
| Benazepril Hcl | Benazepril Hcl | 77 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 36 |
| Flecainide Acetate | Flecainide Acetate | 66 | 29 |
| Ranolazine Er | Ranolazine | 62 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 31 |
| Nitroglycerin | Nitroglycerin | 44 | 36 |
| Omeprazole | Omeprazole | 44 | 24 |
| Potassium Chloride | Potassium Chloride | 44 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 22 |
| Brilinta | Ticagrelor | 43 | 14 |
| Ezetimibe | Ezetimibe | 43 | 20 |
| Simvastatin | Simvastatin | 40 | 18 |
| Cilostazol | Cilostazol | 39 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | 11 |
| Uptravi | Selexipag | 30 | suppressed |
| Atenolol | Atenolol | 29 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 17 |
| Warfarin Sodium | Warfarin Sodium | 29 | 14 |
| Propafenone Hcl | Propafenone Hcl | 28 | 13 |
| Chlorthalidone | Chlorthalidone | 27 | 15 |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Opsumit | Macitentan | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Camzyos | Mavacamten | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Adempas | Riociguat | 11 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,000.87 · 23 records | Philips North America LLC | AVVIGO Guidance System, Barostim Neo System, Coronary Other, IGT Devices Undivided, Kerendia, LEQVIO, LOKELMA, LifeVest, ONPATTRO, Ozempic, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, VIA MATRIX, WAINUA, WINREVAIR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error